Preclinical Oncology CRO Services
Cyagen provides end-to-end oncology CRO services – from advanced animal models to comprehensive drug evaluation and translational insights. Our platform accelerates oncology research with customizable models and validated preclinical solutions.
One-Stop Oncology CRO Solutions
As one of the leading preclinical oncology CRO companies, Cyagen provides comprehensive preclinical CRO solutions for oncology drug evaluation, supporting antibody drugs,
cell and gene therapies, mRNA-based approaches, and more. Our platform covers the full workflow — from diverse
tumor model generation (CDX, PDX, GEM, syngeneic, humanized) to in vivo efficacy studies and in vitro
mechanistic assays. With extensive experience across 200+ oncology projects and support for IND applications, we
help biopharma teams accelerate their oncology pipelines with confidence and precision.
{{ item.title }}
{{static_tabs[0].title}}
Cyagen delivers comprehensive in vivo efficacy evaluation services that simulate clinical settings
with
high fidelity. From tumor
establishment to pharmacodynamic monitoring, our platform supports a wide spectrum of model types
and
therapeutic
modalities—helping clients generate robust, IND-enabling preclinical data.
Base Strain
Search for Models
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
Next Page
Need Customized Evaluation for Your Therapy?
If your desired neuroscience model isn’t listed, our experts are here to help!
Request a Custom Animal Model
>>
{{static_tabs[1].title}}
At Cyagen, we offer advanced in vivo drug delivery and phenotyping services tailored for ophthalmic
studies. From precise ocular
injections to high-resolution imaging and vision behavior analysis, our platform provides
comprehensive
capabilities to evaluate
drug efficacy and safety. Supported by expert personnel and cutting-edge instrumentation, we ensure
consistent, accurate, and
reproducible preclinical results.
Customized Study Design
Designs tailored for evaluating mAbs, mRNA drugs, CAR-T/NK therapies, oncolytic viruses, and
immune checkpoint inhibitors.
- IND-ready timelines & professional consultation included.
Tumor Model Flexibility
Supports subcutaneous, orthotopic, hematologic, and metastatic tumor models using:
- CDX (Cell-Derived Xenograft)
- PDX (Patient-Derived Xenograft)
- GEMM (Genetically Engineered Mouse Models)
- Humanized Immune Mouse Models (e.g., huHSC-C-NKG-ProF)
Endpoints & Technologies
- Tumor volume, body weight, survival ging (bioluminescence/fluorescence)
- Flow cytometry, H&E, IHC, ELISA, qPCR
- Customized readouts for mechanism-of-action or resistance studies
Need Customized Evaluation for Your Therapy?
Case Examples
{{ item.label }}
{{item.context}}
{{ item.context }}
{{static_tabs[2].title}}
Cyagen offers a full suite of in vitro and ex vivo pharmacology services to support oncology drug
discovery and mechanistic studies. These assays complement in vivo models, providing
high-throughput,
reproducible insights into drug cytotoxicity, immune act
Cytotoxicity & Immune Function Assays
- LDH / CTG / CCK-8 viability and cytotoxicity tests
- CAR-T/NK-mediated cell killing & activation
- T/NK cell cytokine secretion and proliferation
- Antibody-dependent cellular cytotoxicity (ADCC)
Molecular & Biomarker Detection
- Western Blot, ELISA, qPCR for expression profiling
- Cytokine panels via Singleplex (ELISA) and Multiplex (Luminex, MSD, FACS CBA)
- DNA/RNA detection via digital PCR and molecular hybridization
Histology & Imaging-Based Analysis
- H&E staining, immunohistochemistry (IHC)
- Immunofluorescence (IF), dual/multiplex labeling
- Fluorescence imaging for tissue localization & distribution
- In vivo biodistribution via IVIS if applicable
Pharmacokinetics & Toxicity (Optional add-on)
- Single or repeat dose toxicity testing
- Genotoxicity, reproductive toxicity, carcinogenicity
- Blood chemistry, organ indices, LC-UV bioanalysis
Looking to Validate Drug Mechanisms or Biomarkers?
Case Examples
{{ item.label }}
{{item.context}}
{{ item.context }}
Our Unique Advantages
Broad Model Coverage for Translational Relevance
Cyagen provides one of the industry’s most extensive tumor model libraries—ranging from CDX, PDX, GEMM, to fully humanized immune mice—enabling clinically relevant assessments for diverse oncology pipelines.
End-to-End Evaluation from Efficacy to Mechanism
From tumor growth curves to biomarker analysis, we support every stage of your study with comprehensive endpoints—IVIS imaging, survival tracking, histology (H&E/IHC), qPCR, flow cytometry, and more.
Proven Success in IND-Enabling Projects
With 200+ oncology studies completed and multiple IND applications supported, our CRO platform combines validated workflows with expert guidance to accelerate your drug development with confidence.
Related Resources
Events & Webinars
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
View Details
Resource Valut
HUGO-GT™ Models：Efficacy Data & Core Advantages for Small Nucleic Acid Drug Therapeutics
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
